As a resolution, the in vivo antitumor activity of rilotumumab was evaluated in xenograft models in which HGF was expressed in either a paracrine or autocrine fashion, demonstrating that rilotumumab could inhibit the growth of autocrine HGF-driven glioblastomas (U-87 and U-118) and paracrine-regulated leiomyosarcoma [16,129,130]. This evidence concerns the gene HGF and glioblastoma.